ASCO Conference Coverage

ASCO: Alcohol Is A Modifiable Risk Factor for Cancer

Seventy percent of Americans surveyed in this year's National Cancer Opinion Survey were unaware that alcohol is a well-established and modifiable risk factor for cancer, the authors noted.

ASCO: CAR T-Cell Therapy Promising for Multiple Myeloma

Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein demonstrated promising results.

ASCO, Cancer Care Ontario Update Recommendations on Brachytherapy in Prostate Cancer

ASCO and Cancer Care Ontario issued a joint update to guidelines for brachytherapy for prostate cancer that take into account new evidence.

ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention

ASCO offers global recommendations for HPV vaccination tailored to structural resource levels of regions.

ONS Partners with ASCO CancerLinQ to Launch CancerLinQ® Ambassadors Program

CancerLinQ® Ambassadors Program is launched to provide support and guidance to practices participating in CancerLinQ®.

ASCO Issues Adjuvant Bisphosphonate in Breast Cancer Guideline

Zoledronic acid and clodranate are the recommended bisphosphonates for the adjuvant treatment of postmenopausal patients with breast cancer.

ASCO Endorses ACS Head and Neck Survivorship Care Guideline

ASCO endorses ACS head and neck survivorship care guideline, which supports health promotion, especially regarding tobacco cessation and dental care.

Nurse-Calling Program Improves Retention Rates From First Treatment Visit

Patients who speak to an oncology nurse prior to their first appointment are significantly more likely to be retained for their treatment.

Hematologic Oral Chemotherapy Clinic Reduces Emergency Department Visits

A hematologic multidisciplinary oral chemotherapy clinic established at a community hospital identified adverse events early and reduced ED visits.

Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms

Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML).

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs